Alia Therapeutics
9.5.2023 10:11:23 CEST | ACCESS Newswire | Press release
MILAN, ITALY / ACCESSWIRE / May 9, 2023 / Alia Therapeutics, a Trento-based start-up specializing in innovative treatments for rare genetic diseases through next-generation gene editing technology, announced the appointment of Adel Nada as an independent member of the Board of Directors.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Adel Nada is Co-founder and Chief Executive Officer of GentiBio, a biotherapeutics company that is developing engineered regulatory T cells (Tregs) programmed to treat autoimmune and inflammatory diseases. Prior to joining GentiBio, Adel was the Chief Medical Officer of Casebia Therapeutics, where he worked on advancing engineered regulatory T cell therapeutics.
Over the past 15 years, he has successfully led translational and immunology programs for experimental and approved therapies, spanning small and large molecules, as well as engineered immune cell products.
Paola Pozzi, Partner at Sofinnova Partners and a member of Alia's Board of Directors, said: "Adel's experience and knowledge of the field will help guide Alia towards the next stage in its development. We feel very fortunate to have such an esteemed leader join our Board of Directors."
Adel Nada, Independent Board Director of Alia, said: "I'm delighted to have been invited to join the board of such a compelling biotech with a very differentiated genome editing platform. I look forward to advancing Alia's platforms and pipeline to enable novel, tailored gene editing strategies that have the potential to overcome current limitations of genome editing and bring more therapies to patients with underserved and currently untreatable diseases and conditions."
Letizia Goretti, Chief Executive Officer of Alia, said: "Adel's experience in biotech is both broad and deep. We are really excited to partner with him as Alia's growth accelerates."
Adel received his medical degree from Alexandria University in Egypt and his master's degree in clinical research from the Pharmacology Dept. at Rush University in Chicago, where he also held an academic position and practiced for 10 years in affiliated hospitals.
About Alia Therapeutics
Alia Therapeutics is an Italian biotech start-up whose mission is to develop innovative treatments for incurable genetic diseases using gene editing technology. The company was founded in October 2018 by Anna Cereseto and a group of researchers from CIBIO, the biotech department of the University of Trento, who discovered the core CRISPR technologies exploited by the start-up. Read more at aliatherapeutics.com
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com
For more information about Sofinnova Telethon, visit https://sofinnovapartners.com/strategy/telethon
Contact
Letizia Goretti
CEO, Alia Therapeutics
info@aliatx.com
SOURCE: Alia Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/753506/Alia-Therapeutics-appoints-Adel-Nada-as-Independent-Board-Director
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Hydrosat and Kazakhstan Gharysh Sapary Sign Agreement to Advance Satellite-Based Water Intelligence Across Kazakhstan and Central Asia25.6.2026 17:00:00 CEST | Press release
BRUSSELS, BE / ACCESS Newswire / June 25, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, and JSC "NC "Kazakhstan Gharysh Sapary" (JSC "NC "KGS"), Kazakhstan's national space company, announced the signing of a Joint Activity Agreement during a ceremony held in Brussels on 23 June 2026. The agreement establishes the framework for a national-scale program to digitize water resources management using satellite-based thermal analytics and AI, with the potential to expand across Central Asia. The agreement was signed as part of the state visit of the Head of State of the Republic of Kazakhstan to Belgium. During the visit, a number of strategic agreements were concluded to advance artificial intelligence, science, digital infrastructure, and space technologies, creating new opportunities for investment, joint research, technology deployment, and international cooperation. Representing Kazakhstan at the signing ceremonies were Deputy Prime
GA-ASI Adapts Ground Control Station to Fly MQ-9B25.6.2026 16:00:00 CEST | Press release
World Leader in UAS Invests in Upgrades That Ease MQ-9B Procurement SAN DIEGO, CA / ACCESS Newswire / June 25, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is working to adapt its Block 30 Ground Control Stations (GCS) to fly the company's newer model MQ-9B SkyGuardian® and SeaGuardian® Remotely Piloted Aircraft. When these upgrades are complete, they will enable current users of the Block 30 system, originally designed to fly the MQ-9A Reaper®, to keep that equipment and use it to operate the more capable aircraft. Current users include the U.S. Air Force, U.S. Marine Corps, the Italian Air Force, the French Air Force, the United Arab Emirates Armed Forces, the Spanish Air Force, and the Royal Netherlands Air Force. GA-ASI developed the MQ-9B through its own internal research and development. The upgraded new aircraft required a new and more powerful GCS. The ongoing work with the Block 30 GCS now means that prospective users with existing stocks of equipment wouldn't ne
TIS Warns that Companies are Underprepared for Impact of ISO 20022 Financial Transaction Standard25.6.2026 15:30:00 CEST | Press release
Treasury Intelligence Solutions (TIS) reports that payment disruption is now reaching corporates as banks enforce stricter data standards under the new standard for transaction messaging, and critical gaps are appearing. BERLIN, DE / ACCESS Newswire / June 25, 2026 / TIS today announced a call to action for corporate treasury, finance, and IT teams: ISO 20022 is no longer a bank-only issue, and companies that treat it as simply a messaging upgrade may face payment delays, rejected transactions, higher manual intervention, and reconciliation problems. TIS is the creator of an award-winning cloud-based platform for managing global cash flow, liquidity, and payments. Hundreds of worldwide clients rely on the TIS platform for $80 billion in daily cash management and $2.7 trillion in annual transaction volume. The TIS call to action stems from the SWIFT global financial communication network's steps to phase in ISO 20022 as the sole standard for interbank payment instructions. The new stand
Envision Pharma Group Promotes Jennifer Lospinoso to President, Riparian25.6.2026 15:00:00 CEST | Press release
FAIRFIELD, CT / ACCESS Newswire / June 25, 2026 / Envision Pharma Group (Envision) has appointed Jennifer (Jenn) Lospinoso as President of Riparian, its business unit focused on pricing, access, and value optimization for pharmaceutical and biotech companies. "Jenn's promotion reflects her exceptional leadership, deep industry expertise, and unwavering commitment to clients," said Tom Langan, CEO of Envision. "Riparian represents a significant growth opportunity for Envision, and I'm confident that Jenn and her team will drive the innovation and excellence that sets us apart and delivers for our clients." Lospinoso came to Envision as part of the 2022 acquisition of Riparian, where she served as a key leader. Jenn has built a reputation as a trusted advisor to some of the industry's leading pharmaceutical companies, guiding manufacturers through commercial strategy implementation and navigating statutory and regulatory changes across government programs, including the development of pr
Pacific Avenue Capital Partners Announces Investment Committee Appointment, New AI Initiative, and Team Expansion25.6.2026 15:00:00 CEST | Press release
LOS ANGELES, CA / ACCESS Newswire / June 25, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced the appointments of Jonathan Sinnott to the Investment Committee, the establishment of a dedicated artificial intelligence team led by Al Rahrooh and supported by Ahsan Hashmi and Alejandro Urrea, and the addition of Tyler Woodhouse, Adolfo Guerra, and Francisco Lima across portfolio operations and compliance, along with a new investment team member, Saiesha Sharma, as an associate. "We remain committed to building the best private equity firm to work at in Los Angeles. Jonathan's appointment to the Investment Committee is a well-deserved recognition of his contributions and I look forward to his continued impact in this expanded role. Additionally, the establishment of our dedicated AI team is a critical initiative for the firm, and one we believe will cr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom